VEGFA and glioma: Thus, the addition of Bevucizumab (anti-VEGF mAb) to radiotherapy and temozolomide in pediatric patients with high-grade gliomas failed to improve event-free survival; these findings were not comparable to those of previous adult trials, thus strongly highlighting the absolute need of performing pediatric-specific studies [79].